Figure 3.
Figure 3. TAK-243 impacts on protein and gene expression profiles. (A) RPPA analysis was performed on MM1.S cells exposed to vehicle or TAK-243. The 45 proteins whose abundance was most enhanced are indicated at the left, whereas the right side shows the 8 whose abundance was most decreased. (B) Western blotting (top panel) was performed to confirm the changes in MCL-1 and c-MYC, with β-actin serving as a loading control. Bortezomib serves as a positive control, and studies were also performed in the presence of Z-VAD-FMK to determine a possible impact of activation of apoptosis on the abundance of these proteins. Changes in protein-expression levels were largely independent of any alterations in the abundance of the respective messenger RNAs (bottom panel). (C) Gene expression profiling was performed on TAK-243–treated cells, and the top 10 dysregulated pathways identified by Ingenuity pathway analysis are indicated.

TAK-243 impacts on protein and gene expression profiles. (A) RPPA analysis was performed on MM1.S cells exposed to vehicle or TAK-243. The 45 proteins whose abundance was most enhanced are indicated at the left, whereas the right side shows the 8 whose abundance was most decreased. (B) Western blotting (top panel) was performed to confirm the changes in MCL-1 and c-MYC, with β-actin serving as a loading control. Bortezomib serves as a positive control, and studies were also performed in the presence of Z-VAD-FMK to determine a possible impact of activation of apoptosis on the abundance of these proteins. Changes in protein-expression levels were largely independent of any alterations in the abundance of the respective messenger RNAs (bottom panel). (C) Gene expression profiling was performed on TAK-243–treated cells, and the top 10 dysregulated pathways identified by Ingenuity pathway analysis are indicated.

Close Modal

or Create an Account

Close Modal
Close Modal